These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 1465648

  • 41. Transfusion-dependent beta thalassemia in Afghanistan: current evidence amid COVID-19 and future recommendations.
    Qaderi S, Mousavi SH, Ahmadi A, Arif S, Madadi S, Ayoubi S, Lucero-Prisno DE.
    Hematology; 2021 Dec; 26(1):432-434. PubMed ID: 34130618
    [No Abstract] [Full Text] [Related]

  • 42. Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study.
    Marshall R, Tricta F, Galanello R, Leoni G, Kirkland D, Minto S, Spino M.
    Mutagenesis; 2003 Sep; 18(5):457-63. PubMed ID: 12960415
    [Abstract] [Full Text] [Related]

  • 43. Bone metabolism in thalassemia.
    Garofalo F, Piga A, Lala R, Chiabotto S, Di Stefano M, Isaia GC.
    Ann N Y Acad Sci; 1998 Jun 30; 850():475-8. PubMed ID: 9668589
    [No Abstract] [Full Text] [Related]

  • 44. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP, Kumar S, Choudhury P, Talukdar B, Puri RK.
    Indian Pediatr; 1993 Jun 30; 30(6):775-8. PubMed ID: 8132258
    [Abstract] [Full Text] [Related]

  • 45. Common queries in thalassemia care.
    Panigrahi I, Marwaha RK.
    Indian Pediatr; 2006 Jun 30; 43(6):513-8. PubMed ID: 16820660
    [Abstract] [Full Text] [Related]

  • 46. METABOLISM OF IRON, CALCIUM AND MAGNESIUM IN HOMOZYGOUS THALASSEMIA.
    ERLANDSON ME, GOLUBOW J, WEHMAN J, SMITH CH.
    Ann N Y Acad Sci; 1964 Oct 07; 119():769-75. PubMed ID: 14219456
    [No Abstract] [Full Text] [Related]

  • 47. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
    Grosse R, Lund U, Caruso V, Fischer R, Janka GE, Magnano C, Engelhardt R, Dürken M, Nielsen P.
    Ann N Y Acad Sci; 2005 Oct 07; 1054():429-32. PubMed ID: 16339692
    [Abstract] [Full Text] [Related]

  • 48. A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity.
    Porter JB, Faherty A, Stallibrass L, Brookman L, Hassan I, Howes C.
    Ann N Y Acad Sci; 1998 Jun 30; 850():483-7. PubMed ID: 9668591
    [No Abstract] [Full Text] [Related]

  • 49. Current trends in management of the beta thalassemias.
    Shah D, Choudhury P, Dubey AP.
    Indian Pediatr; 1999 Dec 30; 36(12):1229-42. PubMed ID: 10745364
    [No Abstract] [Full Text] [Related]

  • 50. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 51. Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules.
    Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.
    Acta Haematol; 2004 Apr 10; 111(4):189-95. PubMed ID: 15153710
    [Abstract] [Full Text] [Related]

  • 52. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.
    Mirbehbahani N, Jahazi A, Rahim Abad HH.
    Hematology; 2012 May 10; 17(3):183-6. PubMed ID: 22664119
    [Abstract] [Full Text] [Related]

  • 53. Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen.
    Piomelli S, Danoff SJ, Becker MH, Lipera MJ, Travis SF.
    Ann N Y Acad Sci; 1969 Nov 20; 165(1):427-36. PubMed ID: 5260165
    [No Abstract] [Full Text] [Related]

  • 54. The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.
    Ballas SK, Zeidan AM, Duong VH, DeVeaux M, Heeney MM.
    Am J Hematol; 2018 Jul 20; 93(7):943-952. PubMed ID: 29635754
    [Abstract] [Full Text] [Related]

  • 55. Oral iron chelation therapy for thalassaemia: an uncertain scene.
    Pippard MJ, Weatherall DJ.
    Br J Haematol; 2000 Oct 20; 111(1):2-5. PubMed ID: 11091177
    [No Abstract] [Full Text] [Related]

  • 56. Systemic Yersinia enterocolitica infection associated with iron overload and deferoxamine therapy.
    Abcarian PW, Demas BE.
    AJR Am J Roentgenol; 1991 Oct 20; 157(4):773-5. PubMed ID: 1892033
    [No Abstract] [Full Text] [Related]

  • 57. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
    Dee CM, Cheuk DK, Ha SY, Chiang AK, Chan GC.
    Br J Haematol; 2014 Nov 20; 167(3):434-6. PubMed ID: 24989901
    [No Abstract] [Full Text] [Related]

  • 58. Effects of desferoxamine on retinal and visual function.
    Lu M, Hansen RM, Cunningham MJ, Eklund SE, Fulton AB.
    Arch Ophthalmol; 2007 Nov 20; 125(11):1581-2. PubMed ID: 17998528
    [No Abstract] [Full Text] [Related]

  • 59. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
    Keshtkaran A, Javanbakht M, Salavati S, Mashayekhi A, Karimi M, Nuri B.
    Transfusion; 2013 Aug 20; 53(8):1722-9. PubMed ID: 23241074
    [Abstract] [Full Text] [Related]

  • 60. Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy.
    Cianciulli P, Sollecito D, Sorrentino F, Forte L, Gilardi E, Massa A, Papa G, Carta S.
    Kidney Int; 1994 Aug 20; 46(2):467-70. PubMed ID: 7967359
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.